PHI with Atrophic pulmonary emphysema
How does this condition affect your private health insurance?
Emphysem pulmonal atrophisch, or atrophic pulmonary emphysema, is a chronic, progressive lung disease primarily characterized by the irreversible destruction and enlargement of the air sacs (alveoli) in the lungs. This damage leads to a loss of elasticity and reduction in the surface area available for gas exchange, making breathing difficult. The "atrophic" aspect emphasizes the wasting or degradation of lung tissue. It often results from long-term exposure to irritants like cigarette smoke, air pollution, or sometimes a genetic deficiency. Symptoms include shortness of breath, chronic cough, wheezing, and chest tightness, progressively worsening over time. The condition impairs lung function significantly.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several months to years, with initial subtle symptoms gradually worsening.
Duration of Illness (Lifetime)
Chronic, lifelong disease with progressive worsening.
Cost of Treatment (Initial)
A few hundred to several thousand dollars for diagnosis and initial management.
Cost of Treatment (Lifetime)
Tens of thousands to hundreds of thousands of dollars, or more, including medications, oxygen therapy, pulmonary rehabilitation, and hospitalizations.
Mortality Rate
Moderate to high, as it is a progressive and incurable disease often leading to respiratory failure or cardiovascular complications.
Risk of Secondary Damages
High, including recurrent respiratory infections, right-sided heart failure (cor pulmonale), pneumothorax, muscle wasting, and significant disability.
Probability of Full Recovery
Extremely low to none, as the destruction of alveolar tissue is irreversible; management focuses on slowing progression and symptom relief.
Underlying Disease Risk
High, commonly associated with chronic bronchitis (forming COPD), cardiovascular diseases, and in a subset, alpha-1 antitrypsin deficiency.